J 2014

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

SLAVÍČEK, Lubomír, Tomáš PAVLÍK, Jiří TOMÁŠEK, Zbyněk BORTLÍČEK, Tomáš BÜCHLER et. al.

Basic information

Original name

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry

Authors

SLAVÍČEK, Lubomír (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Tomáš BÜCHLER (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic), Rostislav VYZULA (203 Czech Republic), Jana PRAUSOVÁ (203 Czech Republic), Jindřich FÍNEK (203 Czech Republic), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

BMC Gastroenterology, London, BioMed Central, 2014, 1471-230X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.365

RIV identification code

RIV/00216224:14110/14:00075327

Organization unit

Faculty of Medicine

UT WoS

000334417600002

Keywords in English

Anti-angiogenic therapy; Chemotherapy; Elderly patients; Overall survival; Progression-free survival

Tags

Tags

International impact, Reviewed
Změněno: 24/4/2015 12:59, Soňa Böhmová

Abstract

V originále

V rámci práce bylo sledováno 3187 pacientů s mCRC léčených bevacizumabem v 1. linii z českého národního registru pacientů s mCRC. Cílem bylo porovnat účinnost a bezpečnost léčby v různých věkových kategoriích.